S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Stock market today: World shares mostly lower as Congress averts a US government shutdown
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
Bank of Japan survey shows manufacturers optimistic about economy
Sam Bankman-Fried must now convince a jury that the former crypto king was not a crook
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
Federal student loan payments are starting again. Here's what you need to know
Facing increasing pressure from customers, some miners are switching to renewable energy
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
Grant program for Black women entrepreneurs blocked by federal appeals court
The death toll in a collapsed gold mine in Zimbabwe expected to rise to 13, vice president says
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Stock market today: World shares mostly lower as Congress averts a US government shutdown
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
Bank of Japan survey shows manufacturers optimistic about economy
Sam Bankman-Fried must now convince a jury that the former crypto king was not a crook
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
Federal student loan payments are starting again. Here's what you need to know
Facing increasing pressure from customers, some miners are switching to renewable energy
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
Grant program for Black women entrepreneurs blocked by federal appeals court
The death toll in a collapsed gold mine in Zimbabwe expected to rise to 13, vice president says
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Stock market today: World shares mostly lower as Congress averts a US government shutdown
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
Bank of Japan survey shows manufacturers optimistic about economy
Sam Bankman-Fried must now convince a jury that the former crypto king was not a crook
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
Federal student loan payments are starting again. Here's what you need to know
Facing increasing pressure from customers, some miners are switching to renewable energy
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
Grant program for Black women entrepreneurs blocked by federal appeals court
The death toll in a collapsed gold mine in Zimbabwe expected to rise to 13, vice president says
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Stock market today: World shares mostly lower as Congress averts a US government shutdown
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
Bank of Japan survey shows manufacturers optimistic about economy
Sam Bankman-Fried must now convince a jury that the former crypto king was not a crook
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
Federal student loan payments are starting again. Here's what you need to know
Facing increasing pressure from customers, some miners are switching to renewable energy
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
Grant program for Black women entrepreneurs blocked by federal appeals court
The death toll in a collapsed gold mine in Zimbabwe expected to rise to 13, vice president says
Top-Rated StocksTop-Rated
NASDAQ:ZNTL

Zentalis Pharmaceuticals (ZNTL) Price Target & Analyst Ratings

$20.06
+0.43 (+2.19%)
(As of 09/29/2023 08:54 PM ET)
Compare
Today's Range
$19.53
▼
$20.27
50-Day Range
$19.63
▼
$28.25
52-Week Range
$15.55
▼
$31.46
Volume
1.10 million shs
Average Volume
700,809 shs
Market Capitalization
$1.42 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$47.50
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media

Zentalis Pharmaceuticals Consensus Rating and Price Target (2023)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Buy
Based on 7 Analyst Ratings

Consensus Analyst Price Target

$47.50
136.79% Upside
High Prediction$70.00
Average Prediction$47.50
Low Prediction$27.00
TypeCurrent
10/2/22 to 10/2/23		1 Month Ago
9/2/22 to 9/2/23		3 Months Ago
7/4/22 to 7/4/23		1 Year Ago
10/2/21 to 10/2/22
Consensus Rating
Buy
Buy
Buy
Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
7 Buy rating(s)
7 Buy rating(s)
8 Buy rating(s)
8 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$47.50$47.50$47.10$61.38
Predicted Upside136.79% Upside110.66% Upside123.19% Upside96.48% Upside
Get Zentalis Pharmaceuticals Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for ZNTL and its competitors with MarketBeat's FREE daily newsletter.


ZNTL Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

ZNTL Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Zentalis Pharmaceuticals Stock vs. The Competition

TypeZentalis PharmaceuticalsMedical CompaniesS&P 500
Consensus Rating Score
3.00
2.66
2.49
Consensus RatingBuyModerate BuyHold
Predicted Upside136.79% Upside869.81% Upside698.21% Upside
News Sentiment RatingPositive News
Positive News
Positive News

Historical Target Prices and Ratings

Export to Excel
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
8/10/2023Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Reiterated RatingOutperform ➝ Outperform$38.00+48.03%
8/10/2023Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetOverweight ➝ Overweight$51.00 ➝ $50.00+93.87%
8/10/2023HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Reiterated RatingBuy ➝ Buy$55.00+115.01%
6/7/2023Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost Target$45.00 ➝ $50.00+98.89%
5/19/2023Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower Target$120.00 ➝ $70.00+162.27%
11/21/2022UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower Target$52.00+147.62%
11/11/2022Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetBuy$55.00 ➝ $28.00+35.20%
11/11/2022Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetOverweight$60.00 ➝ $55.00+165.57%
11/10/2022SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetOutperform$42.00 ➝ $27.00+46.82%
11/10/2022Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetOutperform$80.00 ➝ $50.00+171.89%
(Data available from 10/2/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)












ZNTL Price Target - Frequently Asked Questions

What is Zentalis Pharmaceuticals's consensus rating and price target?

According to the issued ratings of 7 analysts in the last year, the consensus rating for Zentalis Pharmaceuticals stock is Buy based on the current 7 buy ratings for ZNTL. The average twelve-month price prediction for Zentalis Pharmaceuticals is $47.50 with a high price target of $70.00 and a low price target of $27.00. Learn more on ZNTL's analyst rating history.

Do Wall Street analysts like Zentalis Pharmaceuticals more than its competitors?

Analysts like Zentalis Pharmaceuticals more than other Medical companies. The consensus rating for Zentalis Pharmaceuticals is Buy while the average consensus rating for medical companies is Moderate Buy. Learn more on how ZNTL compares to other companies.

Does Zentalis Pharmaceuticals's stock price have much upside?

According to analysts, Zentalis Pharmaceuticals's stock has a predicted upside of 110.66% based on their 12-month price targets.

What analysts cover Zentalis Pharmaceuticals?

Zentalis Pharmaceuticals has been rated by HC Wainwright, Wedbush, and Wells Fargo & Company in the past 90 days.


Stock Ratings Reports and Tools

Related Companies:
Today's Ratings:
Top Rated Stocks:
More Ratings Tools:
This page (NASDAQ:ZNTL) was last updated on 10/2/2023 by MarketBeat.com Staff

My Account -